> Detailanzeige
Fietkau, Rainer
[VerfasserIn];
Grützmann, R.
[VerfasserIn];
Wittel, Uwe Alexander
[VerfasserIn];
Croner, Roland
[VerfasserIn];
Jacobasch, Lutz
[VerfasserIn];
Neumann, Ulf Peter
[VerfasserIn];
Reinacher-Schick, Anke Claudia
[VerfasserIn];
Imhoff, Detlef
[VerfasserIn];
Boeck, Stefan
[VerfasserIn];
Keilholz, Luisa
[VerfasserIn];
Oettle, Helmut
[VerfasserIn];
Hohenberger, Werner
[VerfasserIn];
Golcher, Henriette
[VerfasserIn];
Bechstein, Wolf Otto
[VerfasserIn];
Uhl, Waldemar
[VerfasserIn];
Pirkl, Anna
[VerfasserIn];
Adler, Werner
[VerfasserIn];
Semrau, Sabine
[VerfasserIn];
Rutzner, Sandra
[VerfasserIn];
Ghadimi, Michael
[VerfasserIn];
Lubgan, Dorota
[VerfasserIn];
Grützmann, Robert
[VerfasserIn]
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial
Teilen
Literatur-
verwaltung
Direktlink
Zur
Merkliste
Lösche von
Merkliste
Per Email teilen
Auf Twitter teilen
Auf Facebook teilen
Per Whatsapp teilen
- Medientyp: E-Book; Sonderdruck
- Titel: R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial
- Beteiligte: Fietkau, Rainer [VerfasserIn]; Grützmann, R. [VerfasserIn]; Wittel, Uwe Alexander [VerfasserIn]; Croner, Roland [VerfasserIn]; Jacobasch, Lutz [VerfasserIn]; Neumann, Ulf Peter [VerfasserIn]; Reinacher-Schick, Anke Claudia [VerfasserIn]; Imhoff, Detlef [VerfasserIn]; Boeck, Stefan [VerfasserIn]; Keilholz, Luisa [VerfasserIn]; Oettle, Helmut [VerfasserIn]; Hohenberger, Werner [VerfasserIn]; Golcher, Henriette [VerfasserIn]; Bechstein, Wolf Otto [VerfasserIn]; Uhl, Waldemar [VerfasserIn]; Pirkl, Anna [VerfasserIn]; Adler, Werner [VerfasserIn]; Semrau, Sabine [VerfasserIn]; Rutzner, Sandra [VerfasserIn]; Ghadimi, Michael [VerfasserIn]; Lubgan, Dorota [VerfasserIn]; Grützmann, Robert [VerfasserIn]
- Erschienen: Berlin: Springer Nature, 2021
- Erschienen in: Strahlentherapie und Onkologie ; 197 (2021), 8–18
- Umfang: 1 Online-Ressource (11 Seiten); Diagramme
- Sprache: Englisch
- DOI: 10.1007/s00066-020-01680-2
- ISSN: 1439-099X
- Identifikator:
- Entstehung:
- Anmerkungen:
- Beschreibung: Abstract: Purpose<br>Chemotherapy with or without radiotherapy is the standard in patients with initially nonmetastatic unresectable pancreatic cancer. Additional surgery is in discussion. The CONKO-007 multicenter randomized trial examines the value of radiotherapy. Our interim analysis showed a significant effect of surgery, which may be relevant to clinical practice.<br><br>Methods<br>One hundred eighty patients received induction chemotherapy (gemcitabine or FOLFIRINOX). Patients without tumor progression were randomized to either chemotherapy alone or to concurrent chemoradiotherapy. At the end of therapy, a panel of five independent pancreatic surgeons judged the resectability of the tumor.<br><br>Results<br>Following induction chemotherapy, 126/180 patients (70.0%) were randomized to further treatment. Following study treatment, 36/126 patients (28.5%) underwent surgery; (R0: 25/126 [19.8%]; R1/R2/Rx [n = 11/126; 6.1%]). Disease-free survival (DFS) and overall survival (OS) were significantly better for patients with R0 resected tumors (median DFS and OS: 16.6 months and 26.5 months, respectively) than for nonoperated patients (median DFS and OS: 11.9 months and 16.5 months, respectively; p = 0.003). In the 25 patients with R0 resected tumors before treatment, only 6/113 (5.3%) of the recommendations of the panel surgeons recommended R0 resectability, compared with 17/48 (35.4%) after treatment (p < 0.001).<br><br>Conclusion<br>Tumor resectability of pancreatic cancer staged as unresectable at primary diagnosis should be reassessed after neoadjuvant treatment. The patient should undergo surgery if a resectability is reached, as this significantly improves their prognosis
- Zugangsstatus: Freier Zugang